Climb Bio (CLYM)
Develops antibody programs for immune-mediated diseases.
Something off on this page? Send us feedback.
Develops antibody candidates for immune-mediated diseases, centered on clinical-stage budoprutug and preclinical CLYM116. The two-program pipeline emerged from the Tenet Medicines acquisition and pairs an anti-CD19 program with an anti-APRIL program.
Develops antibody therapies for immune-mediated diseases. Its clinical-stage lead, the anti-CD19 antibody budoprutug, is being studied in primary membranous nephropathy, immune thrombocytopenia, and systemic lupus erythematosus; CLYM116 is a preclinical anti-APRIL antibody for IgA nephropathy.
The two-program pipeline was formed after the 2024 Tenet Medicines acquisition, when the former Eliem Therapeutics pivoted from neuronal-excitability disorders and rebranded as Climb Bio. Budoprutug remains its central clinical asset, while CLYM116 is licensed outside mainland China, Hong Kong, Macau, and Taiwan; the company ceased U.K. operations during the pivot. It now has two disclosed programs rather than the former neuroscience portfolio.
Company facts
Unavailable right now.
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $183.1M · Total debt $1.3M · Total assets $246.3M · Shareholders' equity $239.5M
- Revenue
- $0
- Operating income
- −$15.4M
- Net income
- −$13.5M
No dividends on record.
| Insiders3 holders · as of Jun 30, 2026 | 0.46% | 261.3K shares | |
| Strategic holders1 holder · as of Jan 7, 2026 | 5.94% | 3.40M shares | |
| Otherremainder | 93.60% | 53.60M shares |
57.26M company shares as of Aug 22, 2026 · holders as of their latest filing
The share count has not been confirmed by a second filing; stakes use it as it stands.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Evidence |
|---|---|---|---|
Ra Capital Management, L.P.Strategicdirector, 10 percent owner | 5.94% | 3.40M | Form 4filed Jan 7, 2026 ↗ |
Stephen Basil ThomasInsiderdirector | 0.27% | 154,657 | Form 4filed Feb 27, 2026 ↗ |
Aoife BrennanInsiderdirector, officer: President and CEO | 0.15% | 87,731 | Form 4filed Jun 30, 2026 ↗ |
Emily PimblettInsiderofficer: SVP, Finance & CAO | 0.03% | 18,888 | Form 4filed Jun 20, 2025 ↗ |
Form 4 — an insider's transaction report
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Jun 29, 2026 | Aoife Brennan | director, officer: President and CEO | −30,902 | $13.17 |
| Feb 26, 2026 | Stephen Basil Thomas | director | −16,313 | $7.01 |
| Feb 25, 2026 | Stephen Basil Thomas | director | −33,687 | $7.00 |
| Feb 13, 2026 | Stephen Basil Thomas | director | −10,000 | $5.81 |
| Feb 12, 2026 | Stephen Basil Thomas | director | −90,000 | $5.23 |
- Vertex Pharmaceuticals
Late-stage BAFF/APRIL therapy in IgAN and pMN
- Vera Therapeutics
Approved BAFF/APRIL therapy in primary IgAN
- Biogen
Phase 3 CD38 therapy in IgAN and pMN
- Novartis (ADR)
Phase 3 anti-APRIL program in IgAN
ComparePre-market
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Climb Bio | $15.15 | +0.73% | $861.8M | — | — | — | — |
| Vertex Pharmaceuticals | $556.60 | −0.02% | $141.31B | 32.4 | 28.6 | 11.2 | +12.5% |
| Vera Therapeutics | $35.06 | −1.75% | $2.56B | — | — | — | — |
| Biogen | $222.65 | −0.03% | $32.90B | 39.4 | 16.8 | 3.3 | +3.4% |
| Novartis (ADR) | $162.04 | −0.25% | $308.79B | 24.5 | 17.3 | 5.6 | +0.9% |
| Median | 32.4 | 17.3 | 5.6 | +3.4% |